Kawai Y, Powell A, Arinze I J
J Clin Endocrinol Metab. 1986 May;62(5):827-32. doi: 10.1210/jcem-62-5-827.
Adrenergic receptors in human liver plasma membranes were characterized by radioligand binding assays. The binding of [3H]dihydroalprenolol [( 3H]DHA) to partially purified membranes was rapid, of high affinity, saturable, and stereospecific. The binding of [125I]iodocyanopindolol to the same membranes was also saturable and stereospecific, but extremely slow, and at 37 C required about 6 h for equilibration. The maximum number of binding sites from six livers determined with these two beta-receptor ligands was 36-83 fmol/mg protein. Catecholaminergic agonists competed for these binding sites in the order typical for beta 2-adrenergic receptors. IPS 339 [(tertiarybutylamino-3-ol-2-propyl)oximino-9-fluorene hydrochloride], a beta 2-selective antagonist, was at least 3 orders of magnitude more potent in inhibiting the binding of [3H]DHA than the beta 1-antagonist, atenolol. Computer-aided analysis of the competition curves as well as Hofstee transformations of the binding data indicated the predominance of the beta 2-subtype. The GTP analog guanyl-5'-yl-imidodiphosphate, decreased the binding affinity of the agonist, l-isoproterenol, indicating the modulation of agonist-promoted coupling of the receptors to guanine nucleotide regulatory proteins. The maximum number of binding sites for the binding of [3H]prazosin and [3H]dihydroergocryptine were the same (60-70 fmol/mg protein), indicating that the majority of the alpha-receptors are of the alpha 1-subtype. Competition experiments with prazosin and yohimbine confirmed the predominance of the alpha 1-receptor subtype, although the presence of alpha 2-receptors cannot be completely ruled out. These results indicate that adrenergic receptors in human liver plasma membranes are predominantly of the beta 2- and alpha 1-subtypes.
通过放射性配体结合试验对人肝细胞膜中的肾上腺素能受体进行了表征。[3H]二氢阿普洛尔([3H]DHA)与部分纯化的膜的结合迅速、具有高亲和力、可饱和且具有立体特异性。[125I]碘氰吲哚洛尔与相同膜的结合也是可饱和且具有立体特异性的,但极其缓慢,在37℃下达到平衡需要约6小时。用这两种β受体配体测定的来自六个肝脏的结合位点的最大数量为36 - 83 fmol/mg蛋白质。儿茶酚胺能激动剂以β2肾上腺素能受体典型的顺序竞争这些结合位点。β2选择性拮抗剂IPS 339(盐酸叔丁基氨基-3-醇-2-丙基肟基-9-芴)在抑制[3H]DHA结合方面比β1拮抗剂阿替洛尔至少强3个数量级。对竞争曲线的计算机辅助分析以及结合数据的霍夫斯泰变换表明β2亚型占主导地位。鸟苷-5'-基-亚氨基二磷酸(GTP类似物)降低了激动剂l-异丙肾上腺素的结合亲和力,表明受体与鸟嘌呤核苷酸调节蛋白的激动剂促进偶联受到调节。[3H]哌唑嗪和[3H]二氢麦角隐亭结合的结合位点最大数量相同(60 - 70 fmol/mg蛋白质),表明大多数α受体是α1亚型。用哌唑嗪和育亨宾进行的竞争实验证实了α1受体亚型占主导地位,尽管不能完全排除α2受体的存在。这些结果表明人肝细胞膜中的肾上腺素能受体主要是β2和α1亚型。